Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study
Abstract Background There are novel medications approved for the treatment of hereditary transthyretin amyloidosis (ATTRv), classified as transthyretin (TTR) stabilizers or gene silencers. While many patients may be on both classes of medications, there is no data available on the safety and efficac...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BMC
2024-05-01
|
| Sarja: | Orphanet Journal of Rare Diseases |
| Aiheet: | |
| Linkit: | https://doi.org/10.1186/s13023-024-03198-7 |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|